What the statement says, in brief
On July 16, 2026, the Endocrine Society published a statement on testosterone replacement therapy that reads as a reminder of first principles. A diagnosis of low testosterone, which the Society calls hypogonadism, needs two things together: symptoms of testosterone deficiency, and consistently low, accurately measured total and free testosterone in the blood.
Around that core, the statement makes five practical points. Symptoms alone are not diagnostic. The same diagnostic approach applies at any age. Testing should use at least two early-morning fasting samples, with a common clinical threshold near 300 ng/dL, measured by a standardized assay. Men whose low testosterone is tied to excess weight, with no other cause found, should usually try weight loss first. And because long-term safety is not settled, treatment needs risk assessment up front and monitoring throughout.
This summary paraphrases the Society’s press release. For exact wording, read the statement itself, and expect the Society’s full clinical guideline to carry more detail.
Who should be diagnosed
The statement draws a firm line around diagnosis. It says terms such as “age-related,” “late-onset” and “functional” hypogonadism are hard to define in practice and tend to blur the difference between treatable disease and normal aging. Its answer is to drop the labels and apply one definition to every man: symptoms plus consistently low, accurately measured testosterone.
It also takes a position on testing men without symptoms. The Society found insufficient evidence to support population-level screening. Testing makes sense when there is a reason to suspect deficiency, not as a routine number collected from everyone over a certain age.
Reversible causes come before treatment. The statement names obesity and medicines such as corticosteroids and opioids as causes to rule out first, which matches the Society’s earlier 2018 clinical practice guideline. Our page on medicines that lower testosterone lists the common ones.
The lab expectations, line by line
Most of the practical change for patients sits in how testosterone is measured. Here is what the statement expects and what it looks like in practice.
| Expectation | What it means for your blood draw |
|---|---|
| At least two tests | One low result is a starting point, not a diagnosis |
| Early morning | Testosterone peaks in the morning, so afternoon draws can mislead |
| Fasting | Eating can lower a testosterone reading, so draws are done before breakfast |
| Threshold near 300 ng/dL | A common clinical cutoff, read alongside symptoms and free testosterone |
| CDC HoST-certified assay | Standardized, harmonized assays give comparable results across labs |
| Total and free testosterone | Free testosterone matters when binding proteins are unusually high or low |
The assay point is easy to overlook. The statement warns that non-standardized assays can give different answers for the same blood sample, which leads to both over- and under-diagnosis. Labs certified through the CDC’s Hormone Standardization (HoST) program have been checked against a reference method. The AUA guideline makes a related point, asking for the repeat test at the same laboratory with the same assay.
If you want to see how timing, food and sleep shift a result, our pages on morning testosterone test timing and why a repeat testosterone test matters go deeper.
Who the Society expects to benefit, and who should start elsewhere
The statement is clear that testosterone therapy at roughly the level a man would normally produce has real benefits for men whose low testosterone comes from a disease of the testes, pituitary or hypothalamus. Those are the men the treatment was designed for.
For men who are overweight or obese, defined in the statement as a BMI above 27, and who have no other identified cause, weight loss is typically the first-line therapy. That does not rule out testosterone forever. It means the first plan addresses the cause, because excess weight lowers testosterone and losing weight often raises it. Our page on obesity and low testosterone explains the link.
What it says about safety
The statement leans on the TRAVERSE trials, which enrolled more than 5,200 men followed for one to four years. They found no meaningful increase in heart attack or stroke. They did find roughly a 50% relative increase in pulmonary embolism and more bone fractures in men given testosterone. Long-term safety, including for prostate cancer, has not been established, and the Society is calling for a long-term “Men’s Health Initiative” modeled on the Women’s Health Initiative.
Our articles on the TRAVERSE heart safety results and on testosterone and blood clots unpack those findings.
The context: an FDA review of testosterone
The statement did not appear in a vacuum. In December 2025 the FDA opened a request for information for its expert panel on testosterone therapy for men, and the Society filed written comments in February 2026. In that letter it noted that the risk of high red blood cell counts, infertility and dependency rises with higher dose and longer use, and that testosterone ester injections generally produce higher, more sustained levels than gels and should be used with extra care.
Read together, the comments and the statement point the same way: treat the right men, measure carefully, and keep watching.
How a labs-first workflow lines up
At Ultimate Male, testosterone evaluations are built around the same steps. Blood is drawn on site at our San Gabriel and Downey clinics, scheduled in the morning, with results in 24 to 48 hours. A single low result leads to a repeat draw rather than a treatment decision, and free testosterone, SHBG, LH and FSH are added when the picture calls for them. The TRT pre-screening panel covers total testosterone, estradiol, PSA and a complete blood count before any treatment decision.
Your consultation with a PA-C or MD then asks the statement’s questions: do the symptoms fit, are the numbers consistently low, and is there a reversible cause such as weight, sleep or medication? If the answer is yes on all counts, the visit turns to testosterone therapy options and monitoring. If not, you leave with a plan for what to test or change next. For a side-by-side look at how the two major guidelines differ, see AUA vs Endocrine Society on low testosterone.
